Intervacc awarded grant to optimise production processes for a fusion protein, which is one component of a prototype vaccine for pigs
Stockholm, August 17, 2023 - Intervacc AB (publ) announces that it has been awarded an “industrial research” grant from Vinnova as part of a project with Testa Center, Uppsala, Sweden, to optimise the manufacturing processes of one component for a prototype vaccine for pigs.
Intervacc’s innovative technology utilises fusion proteins in vaccines to generate broad-acting immune responses that provide protection to animals from complex bacterial diseases. Streptococcus suis causes meningitis, sepsis and arthritis in young piglets, leading to significant costs to the pig industry throughout